Quick Heal board to review June 2026 results on July 30

Board meeting set for July 30, 2026

Quick Heal Technologies has informed that its board of directors will meet on July 30, 2026. The agenda is to review and approve the company’s standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. For investors, the June-quarter numbers will be the next formal update after a volatile FY26 in which quarterly performance swung between losses and a short-lived turnaround. The board meeting also becomes a key calendar item because recent results have shown sharp movement in both revenue and profitability.

What the board will consider

The company has said the board will consider unaudited financial results at both the standalone and consolidated levels for the quarter ended June 30, 2026. The focus on both sets of numbers matters because Quick Heal reports consolidated performance including subsidiaries, while standalone reflects the parent entity’s operations. The disclosure does not provide additional guidance on expected performance, and no specific operational updates for the June 2026 quarter were included with the meeting intimation.

Why this update matters after a choppy FY26

The board review comes after FY26 showed pressure in some quarters, including a weak March 2026 quarter, alongside a stronger September 2025 quarter. Quick Heal has already reported a consolidated net loss of ₹5.51 crore in Q1 FY26 (quarter ended June 30, 2025), which it attributed to consumer headwinds. The same period also included detailed quarterly cost and margin movements, indicating that operating performance and expenses remained a key swing factor.

Recent disclosures: December 2025 (Q3 FY26) results announced on Jan 29, 2026

Quick Heal Technologies Limited announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26) on January 29, 2026. The company also informed the BSE that a board meeting was scheduled on January 29, 2026 to consider and approve un-audited financial results for the quarter ended December 31, 2025.

For Q3 FY26, the figures cited include revenue of ₹70.6 crore versus ₹71.5 crore in Q3 FY25 (a change of -1%). EBITDA was ₹-3.8 crore versus ₹0.5 crore in Q3 FY25, with an EBITDA margin of -5.3% for Q3 FY26. PAT was ₹0.1 crore versus ₹6.6 crore in Q3 FY25, a change of -98%, and PAT margin was 0.2% for Q3 FY26. These numbers framed the December-quarter performance as weak on profitability despite broadly steady revenue.

March 2026 quarter: revenue fall and deeper losses

Reported consolidated quarterly numbers for Quick Heal Technologies show net sales of ₹48.73 crore in March 2026, down 25.19% from ₹65.14 crore in March 2025. Quarterly net loss was ₹19.94 crore in March 2026, compared with a net loss of ₹3.25 crore in March 2025. EBITDA was negative at ₹25.57 crore in March 2026, compared with ₹2.88 crore in March 2025.

On the standalone side, the company reported net sales of ₹48.77 crore in March 2026, down 25.12% from ₹65.13 crore in March 2025. Standalone quarterly net loss was ₹19.91 crore in March 2026 versus ₹2.68 crore in March 2025, while EBITDA stood negative at ₹25.54 crore in March 2026 compared with ₹2.31 crore in March 2025.

The company also disclosed that revenue from operations for Q4 FY26 was ₹48.73 crore, a YoY decline of 25.19% from ₹65.14 crore in Q4 FY25 and a QoQ decline of 31.88% from ₹71.54 crore in Q3 FY26.

FY26 full-year performance: revenue decline and loss

For the full year ended March 2026, Quick Heal reported a net loss of ₹10.93 crore, compared with a net profit of ₹5.04 crore in the year ended March 2025. Full-year sales declined 6.62% to ₹261.02 crore in FY26 from ₹279.53 crore in FY25. These full-year numbers provide the broader context in which the June 2026 quarter will be assessed, especially after the sharp deterioration in the March 2026 quarter.

Q1 FY26: June 2025 quarter loss and operating pressure

Quick Heal Technologies Limited reported a net loss after tax (PAT) of ₹5.51 crore for the quarter ended June 30, 2025 (Q1 FY26). In the detailed quarterly table for the June 2025 quarter, total revenue was ₹57.23 crore, down 12.14% QoQ from ₹65.14 crore (March 2025) and down 18.58% YoY from ₹70.29 crore (June 2024). Net income (loss) was ₹-5.51 crore for June 2025 versus ₹-3.25 crore for March 2025 and ₹4.03 crore for June 2024.

The same table showed operating income of ₹-12.69 crore for June 2025 (versus ₹-12.11 crore in March 2025). Total operating expense was ₹69.92 crore for June 2025, and selling, general and admin expenses were ₹43.89 crore. The diluted normalized EPS was ₹-1.00 for June 2025.

Q2 FY26: turnaround quarter highlighted by management commentary

Quick Heal also reported that Q2 FY26 saw a strong turnaround after a Q1 FY26 loss. The company cited 13.6% YoY revenue growth to ₹83.5 crore and a 90.6% surge in PAT to ₹7.9 crore in Q2 FY26, supported by AI innovations and enterprise momentum. Separately, it disclosed Q2 FY26 EBITDA margin of 11.1% (versus 4.2% in Q2 FY25 and -17.0% in Q1 FY26). These disclosures show that profitability has been highly sensitive to execution and segment demand.

Auditor review for Q3 FY26: clean limited review conclusion

The company’s independent auditor’s review report (MS KA & Associates, Chartered Accountants) covered a limited review under Ind AS 34 and SEBI listing regulations. The conclusion reported no qualifications, concerns, or issues, stating that nothing came to the auditor’s attention indicating material misstatements or non-compliance with accounting standards. It also noted that subsidiaries’ interim financials (Quick Heal Technologies America Inc. and Seqrite Technologies DMCC) are unaudited but considered immaterial to the Group.

Key numbers investors have in hand before the July 30 meeting

The July 30, 2026 board meeting is expected to put a fresh set of quarterly numbers on record for the quarter ended June 30, 2026. Ahead of that, investors have a recent trail of quarterly and annual figures that show: revenue compression in the March 2026 quarter, a full-year FY26 revenue decline, and sharp fluctuations in profitability across FY26 quarters. With revenue reported at ₹48.73 crore in the March 2026 quarter, the June 2026 quarter will be compared closely with both the immediately preceding quarter and the year-ago quarter, once results are released.

Snapshot table: reported performance points cited in disclosures

Timeline of recent result-related events

Conclusion

Quick Heal Technologies’ July 30, 2026 board meeting will consider unaudited standalone and consolidated results for the quarter ended June 30, 2026. The update comes after FY26 saw a revenue decline to ₹261.02 crore and a full-year net loss of ₹10.93 crore, alongside sharp quarterly swings including a loss of ₹19.94 crore in the March 2026 quarter. Investors will look to the June 2026 quarter disclosure for evidence of whether performance stabilised after the weak March quarter, with the company’s next formal numbers expected following the board’s review and approval.